Mesa Laboratories Beheer

Beheer criteriumcontroles 2/4

De CEO Mesa Laboratories is Gary Owens, benoemd in Sep2017, heeft een ambtstermijn van 7.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 5.44M, bestaande uit 13.9% salaris en 86.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.8% van de aandelen van het bedrijf, ter waarde € 4.61M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.2 jaar en 4.5 jaar.

Belangrijke informatie

Gary Owens

Algemeen directeur

US$5.4m

Totale compensatie

Percentage CEO-salaris	13.9%
Dienstverband CEO	7.2yrs
Eigendom CEO	0.8%
Management gemiddelde ambtstermijn	7.2yrs
Gemiddelde ambtstermijn bestuur	4.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Gary Owens's beloning veranderd ten opzichte van Mesa Laboratories's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$246m
Jun 30 2024	n/a	n/a	-US$250m
Mar 31 2024	US$5m	US$754k	-US$254m
Dec 31 2023	n/a	n/a	US$948k
Sep 30 2023	n/a	n/a	-US$717k
Jun 30 2023	n/a	n/a	US$2m
Mar 31 2023	US$5m	US$733k	US$930k
Dec 31 2022	n/a	n/a	-US$1m
Sep 30 2022	n/a	n/a	-US$4m
Jun 30 2022	n/a	n/a	-US$2m
Mar 31 2022	US$18m	US$579k	US$2m
Dec 31 2021	n/a	n/a	US$8m
Sep 30 2021	n/a	n/a	US$5m
Jun 30 2021	n/a	n/a	US$4m
Mar 31 2021	US$3m	US$524k	US$3m
Dec 31 2020	n/a	n/a	-US$2m
Sep 30 2020	n/a	n/a	-US$2m
Jun 30 2020	n/a	n/a	-US$2m
Mar 31 2020	US$3m	US$600k	US$2m
Dec 31 2019	n/a	n/a	US$5m
Sep 30 2019	n/a	n/a	US$10m
Jun 30 2019	n/a	n/a	US$8m
Mar 31 2019	US$3m	US$520k	US$7m
Dec 31 2018	n/a	n/a	US$10m
Sep 30 2018	n/a	n/a	-US$2m
Jun 30 2018	n/a	n/a	-US$249k
Mar 31 2018	US$1m	US$417k	-US$3m

Compensatie versus markt: De totale vergoeding ($USD 5.44M ) Gary } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.41M ).

Compensatie versus inkomsten: De vergoeding van Gary is gestegen terwijl het bedrijf verliesgevend is.

CEO

Gary Owens (56 yo)

7.2yrs

Tenure

US$5,435,566

Compensatie

Mr. Gary M. Owens has been Chief Executive Officer, President and Director of Mesa Laboratories, Inc. since September 1, 2017. Mr. Owens joined as Chief Operating Officer in March 2017. Mr. Owens served as...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Gary Owens	CEO, President & Director	7.2yrs	US$5.44m	0.80% € 4.6m
John Sakys	VP, CFO & Chief Accounting Officer	12.1yrs	US$1.94m	0.22% € 1.3m
Brian Archbold	Senior Vice President of Continuous Improvement	6.8yrs	US$1.62m	0% € 0

7.2yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van MLI is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Gary Owens	CEO, President & Director	7.2yrs	US$5.44m	0.80% € 4.6m
Shiraz Ladiwala	Lead Independent Director	3.1yrs	US$220.03k	0.057% € 327.2k
John Sullivan	Independent Chairman of the Board	15.7yrs	US$255.13k	1.34% € 7.7m
R. Tripeny	Independent Director	2.4yrs	US$220.13k	0.049% € 285.1k
Mark Capone	Independent Director	less than a year	US$90.03k	0.013% € 77.1k
Shannon Hall	Independent Director	4.5yrs	US$220.13k	0.051% € 296.5k
Jennifer Alltoft	Independent Director	5.7yrs	US$220.13k	0.064% € 369.8k

4.5yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MLI wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.5 jaar).

Mesa Laboratories Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

CEO, President & Director recently sold €529k worth of stock

Mesa Laboratories, Inc., Annual General Meeting, Aug 30, 2024

Mesa Laboratories, Inc. Appoints Mark Capone to Its Board of Directors

Mesa Laboratories, Inc., Annual General Meeting, Aug 25, 2023

Mesa Laboratories, Inc. Announces John B. Schmieder, Member of the Board of Directors, Chair of the Nominating and Governance Committee, and Member of the Audit Committee Decide Not to Stand for Re-Election

Mesa Laboratories, Inc. Appoints Tony Tripeny as Member of Audit Committee

Recent updates

Second quarter 2025 earnings released: EPS: US$0.63 (vs US$0.23 loss in 2Q 2024)

CEO, President & Director recently sold €529k worth of stock

First quarter dividend of US$0.16 announced

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 16, 2024

Fourth quarter dividend of US$0.16 announced

Mesa Laboratories, Inc., Annual General Meeting, Aug 30, 2024

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on September 16, 2024

Mesa Laboratories, Inc. announced delayed annual 10-K filing

Mesa Laboratories, Inc. announced delayed annual 10-K filing

Full year 2024 earnings released: US$47.21 loss per share (vs US$0.17 profit in FY 2023)

Mesa Laboratories, Inc. Reports Impairment of Goodwill and Long-Lived Assets for the Fourth Quarter Ended March 31, 2024

New minor risk - Share price stability

Upcoming dividend of US$0.16 per share

Third quarter dividend of US$0.16 announced

Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on June 14, 2024

New minor risk - Share price stability

Mesa Laboratories, Inc. to Report Q4, 2024 Results on May 24, 2024

Upcoming dividend of US$0.16 per share

Third quarter 2024 earnings released: EPS: US$0.39 (vs US$0.084 in 3Q 2023)

Mesa Laboratories, Inc. Appoints Mark Capone to Its Board of Directors

Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on March 15, 2024

Mesa Laboratories, Inc. to Report Q3, 2024 Results on Feb 05, 2024

Upcoming dividend of US$0.16 per share at 0.7% yield

New minor risk - Share price stability

Second quarter 2024 earnings released: US$0.23 loss per share (vs US$0.24 profit in 2Q 2023)

Mesa Laboratories, Inc. (NasdaqGS:MLAB) entered into a definitive agreement to acquire Beijing GKE Science & Technology Co. LTD for €5 million.

Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Sterilization indicators business of GKE-GmbH and SAL GmbH from Gke-GmbH for €80 million.

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 15, 2023

Mesa Laboratories, Inc. to Report Q2, 2024 Results on Nov 06, 2023

Upcoming dividend of US$0.16 per share at 0.5% yield

First quarter 2024 earnings released: US$0.10 loss per share (vs US$0.27 loss in 1Q 2023)

New minor risk - Shareholder dilution

Mesa Laboratories, Inc., Annual General Meeting, Aug 25, 2023

Mesa Laboratories, Inc. to Report Q1, 2024 Results on Aug 03, 2023

Full year 2023 earnings released: EPS: US$0.17 (vs US$0.36 in FY 2022)

Now 24% undervalued after recent price drop

Upcoming dividend of US$0.16 per share at 0.4% yield

Mesa Laboratories, Inc. Announces John B. Schmieder, Member of the Board of Directors, Chair of the Nominating and Governance Committee, and Member of the Audit Committee Decide Not to Stand for Re-Election

Upcoming dividend of US$0.16 per share at 0.4% yield

Third quarter 2023 earnings released: EPS: US$0.084 (vs US$0.39 loss in 3Q 2022)

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on March 15, 2023

Mesa Laboratories, Inc. to Report Q3, 2023 Results on Feb 06, 2023

Now 21% undervalued after recent price drop

Upcoming dividend of US$0.16 per share

Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Substantially all of the assets and certain liabilities from Belyntic GmbH.

Mesa Laboratories, Inc. Appoints Tony Tripeny as Member of Audit Committee

Second quarter 2023 earnings released: EPS: US$0.24 (vs US$0.71 in 2Q 2022)

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 15, 2022

Upcoming dividend of US$0.16 per share

Independent Director recently sold €196k worth of stock

Independent Director recently bought €98k worth of stock

First quarter 2023 earnings released: US$0.27 loss per share (vs US$0.39 profit in 1Q 2022)

Mesa Laboratories, Inc., Annual General Meeting, Jul 26, 2022

Mesa Labs Declares Quarterly Dividend, Payable on September 15, 2022

Mesa Laboratories, Inc. Appoints Tony Tripeny to Its Board of Directors

CEO, President & Director recently sold €313k worth of stock

Full year 2022 earnings released

Upcoming dividend of US$0.16 per share

Mesa Laboratories, Inc. Announces Termination of Greg DiNoia as Senior Vice President of Commercial Operations, Effective June 30, 2022

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on June 15, 2022

Upcoming dividend of US$0.16 per share

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Upcoming dividend of US$0.16 per share

Insider recently sold €78k worth of stock

Second quarter 2022 earnings released: EPS US$0.71 (vs US$0.52 in 2Q 2021)

Mesa Laboratories, Inc. (NasdaqGS:MLAB) entered into a definitive agreement to acquire Agena Bioscience, Inc. from its shareholders for approximately $300 million.

Independent Director recently sold €137k worth of stock

Upcoming dividend of US$0.16 per share

Insider recently sold €152k worth of stock